Why did Ablynx board chairman Peter Fellner resign in wake of Novo's buyout offer?; Amgen vet Richard Paulson tapped to run Ipsen North America
→ What’s happening at Ablynx? On the same day Danish biopharma Novo Nordisk $NVO went public with its latest, $3.1 billion offer to buy Ablynx $ABLX, the Belgian biotech announced that Peter Fellner has decided to resign from its board. That abrupt departure triggered a lot of buzz that the unusual overture from Novo — not the kind of company you might typically find muscling a buyout — has triggered some dissension in the board. A former member of the advisory group to Novo Nordisk Foundation’s investing arm, Fellner has been on multiple corporate boards. Bo Jesper Hansen, a non-executive director and ex-CEO of Swedish Orphan International, replaced him as chairman.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.